Vonoprazan-based regimens showed a higher H. pylori eradication rate across a variety of subgroups when compared to triple therapy based on the proton pump inhibitor lansoprazole, according to the authors of a poster presentation at Digestive Disease Week 2023.

Vonoprazan is a potassium-competitive acid blocker approved in the US for the treatment of H. pylori infection in adults.

The pHalcon HP trial, the largest Phase 3 registration trial ever conducted of Helicobacter pylori (H pylori) infection, demonstrated that dual therapy of 20 mg vonoprazan twice daily with 1 g of amoxicillin 3 times per day or triple therapy of vonoprazan 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, twice daily, was superior to triple therapy of lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg, twice daily for 14 days in eradicating H pylori among adult patients who were treatment-naïve.

In this subgroup study, the researchers included 992 patients. “The magnitude of treatment effect for vonoprazan dual therapy and vonoprazan triple therapy vs. lansoprazole triple therapy were generally similar across subgroups based on baseline demographics and clinical characteristics (age, sex, race, ethnicity, region, and body mass index),” the authors concluded.

—Rebecca Mashaw

Reference:

Chey WD, Mégraud F, Laine L, et al. Helicobacter pylori eradication rates with vonoprazan: a subgroup analysis from the phase 3 Phalcon HP trial. Presentation Number: Sa1373.  Presented at: Digestive Disease Week. May 6, 2023. Chicago, Illinois.